Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

NCT02438722 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02438722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02438722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2/3
Overall status
Completed
Start date
May 7, 2015
Completion date
April 17, 2026
Enrollment
174 (actual)
Sites
638

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer